Like pls_老虎社区_美港股上老虎

2021-12-01

Like pls

Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在FDA顾问以微弱优势支持Covid Pill后，默克股票是买入还是卖出？</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":603062571,"tweetId":"603062571","gmtCreate":1638341257058,"gmtModify":1638341257199,"author":{"id":3569243948486771,"idStr":"3569243948486771","authorId":3569243948486771,"authorIdStr":"3569243948486771","name":"EdInvesting","avatar":"https://static.tigerbbs.com/3f2b5d72aa406299a552424310e264b8","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":32,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>Like pls&nbsp;</body></html>","htmlText":"<html><head></head><body>Like pls&nbsp;</body></html>","text":"Like pls","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/603062571","repostId":1170675098,"repostType":4,"repost":{"id":"1170675098","kind":"news","pubTimestamp":1638340930,"share":"https://www.laohu8.com/m/news/1170675098?lang=zh_CN&edition=full","pubTime":"2021-12-01 14:42","market":"us","language":"en","title":"Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在FDA顾问以微弱优势支持Covid Pill后，默克股票是买入还是卖出？</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1170675098","media":"Investors","summary":"Food and Drug Administration advisors recommended Merck's (MRK) Covid pill for some patients in late","content":"Food and Drug Administration advisors recommended&nbsp;Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.<blockquote>推荐食品和药物管理局顾问默克默克(MRK)将于11月底为部分患者提供新冠药物，但默克股价仍面临压力。</blockquote> The FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.<blockquote>FDA抗菌药物咨询委员会于11月30日以13票对10票的投票结果表示，与Ridgeback Biotherapeutics合作的药丸的益处大于其风险。这种名为molnupiravir的药丸降低了具有严重疾病危险因素的轻度至中度Covid患者住院或死亡的风险。</blockquote> Next, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.<blockquote>接下来，FDA将对该药物进行全面审查。该机构不受委员会指导的约束。它还可能批准该药物用于广泛的群体，尽管默克公司迄今为止只有未接种疫苗的患者的测试结果。小组成员指出，人们对孕妇使用莫努匹拉韦表示担忧。</blockquote> Merck is going up against&nbsp;Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.<blockquote>默克正在对抗辉瑞（PFE）。两家公司测试了一组类似的患者。但当患者在症状出现后五天内开始治疗时，默克公司的药物将严重后果的风险降低了30%。辉瑞的两片疗法在三天内治疗时将风险降低了89%。</blockquote> Prior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.<blockquote>在与辉瑞(Pfizer)并列暴跌之前，默克(Merck)股价处于三年来的高点。该公司超出了第三季度的预期，并提供了乐观的2021年前景，其中不包括抗病毒药物的潜在影响。该药丸刚刚在英国获得授权，将以Lagevrio的名称销售。</blockquote> Merck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.<blockquote>默克公司已经与美国政府达成了170万个疗程的莫努匹拉韦的协议。此外，它还同意向英国供应48万个疗程的该药物。它计划在2021年制作1000万门课程，在2022年至少制作2000万门课程。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售额最高</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益增长28%至每股1.75美元，销售额飙升20%至131.5亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导欧加农（OGN）分拆。该制药公司将全年调整后利润预期上调至每股5.65美元至5.70美元，销售额为474亿美元至479亿美元。两项指标均超出预期。而且它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物Keytruda。Keytruda占第三季度总销售额的三分之一以上。Keytruda销售额增长22%，达到45.3亿美元。其人乳头瘤病毒疫苗Gardasil的销售额飙升68%，达到19.9亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物Januvia的收入下降了1%，至13.4亿美元。默克公司报告称，由于新冠疫苗在美国占据优先地位，其肺炎疫苗Pneumovax 23的销量下降了26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合CAN SLIM投资规则，该规则建议投资者寻找近期季度增长率为20%-25%或更高的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.<blockquote>FactSet调查的分析师预计默克本季度每股收益为1.54美元，销售额为132亿美元。与去年同期相比，盈利将飙升近22%，销售额将增长5%以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标对默克有何影响？</blockquote> As of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至11月30日收盘，默克股价年内下跌超过4%。股价最近创下至少三年来的新高，但此后一直在下跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克的销售额增长了2.5%，达到479.9亿美元。这一增长率较2019年11%的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.<blockquote>分析师预计2021年销售额将小幅增长至484.9亿美元。收入预计将增长2.7%，达到每股5.81美元。此前，2020年将增长14%。</blockquote> The stock ranks fifth by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业中的综合评级排名第五。在《投资者商业日报》追踪的197家集团中，这家拥有33家公司的医疗道德药品集团排名中等，第95位。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠协议</blockquote> Merck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.<blockquote>默克公司的molnupiravir现已在英国获得授权。默克公司将向英国供应48万个疗程的该药物，目前以Lagevrio品牌销售。既然FDA的顾问已经推荐了molnupiravir，整个机构将考虑该药物。</blockquote> The U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.<blockquote>默克公司在美国购买170万门课程的交易价值12亿美元。如果成功，molnupiravir可能会在今年年底前进入美国市场。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药公司（AVIR）和Enanta制药(ENTA)正在研究口服新冠药物。罗氏(RHHBY)最近退出了与Atea的Covid抗病毒药物交易。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析师表示，与抗体药物相比，这些药物可能为新冠病毒的非住院治疗提供更容易的途径再生元制药（REGN），礼来公司（LLY）及维尔生物技术（来）。抗体药物必须由卫生保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心莫努匹拉韦的作用方式可能会给未出生婴儿的DNA带来突变。因此，FDA顾问对是否推荐孕妇使用它犹豫不决。</blockquote> Further, Merck and&nbsp;Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.<blockquote>此外，默克和吉利德科学（GILD）开始了一项2期研究，测试他们口服HIV治疗的组合。这些药物被称为islatravir和lenacapavir，可以在体内停留很长时间。这意味着患者可以减少服药的频率。在这种情况下，这些公司正在测试每周给药方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克最近也完成了对Acceleron的收购。</blockquote> In early March, President Joe Biden announced Merck would help&nbsp;Johnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克公司将提供帮助强生公司(JNJ)生产其新冠疫苗。默克公司将从生物医学高级研究与发展局获得2.688亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据CAN SLIM投资规则，不，默克股票目前不值得买入。股价已经反复突破了之前的突破，并引发了多个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利都可能低于预期。预计本季度的销售额不会达到这一目标。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大型股票可以在不实现大幅增长的情况下增加涨幅。</blockquote>","source":"lsy1638341066627","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在FDA顾问以微弱优势支持Covid Pill后，默克股票是买入还是卖出？</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Merck Stock A Buy Or Sell After FDA Advisors Narrowly Endorse Covid Pill?<blockquote>在FDA顾问以微弱优势支持Covid Pill后，默克股票是买入还是卖出？</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nInvestors2021-12-01 14:42\n\n</h4>\n</header>\n<article>\nFood and Drug Administration advisors recommended&nbsp;Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.<blockquote>推荐食品和药物管理局顾问默克默克(MRK)将于11月底为部分患者提供新冠药物，但默克股价仍面临压力。</blockquote> The FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.<blockquote>FDA抗菌药物咨询委员会于11月30日以13票对10票的投票结果表示，与Ridgeback Biotherapeutics合作的药丸的益处大于其风险。这种名为molnupiravir的药丸降低了具有严重疾病危险因素的轻度至中度Covid患者住院或死亡的风险。</blockquote> Next, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.<blockquote>接下来，FDA将对该药物进行全面审查。该机构不受委员会指导的约束。它还可能批准该药物用于广泛的群体，尽管默克公司迄今为止只有未接种疫苗的患者的测试结果。小组成员指出，人们对孕妇使用莫努匹拉韦表示担忧。</blockquote> Merck is going up against&nbsp;Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.<blockquote>默克正在对抗辉瑞（PFE）。两家公司测试了一组类似的患者。但当患者在症状出现后五天内开始治疗时，默克公司的药物将严重后果的风险降低了30%。辉瑞的两片疗法在三天内治疗时将风险降低了89%。</blockquote> Prior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.<blockquote>在与辉瑞(Pfizer)并列暴跌之前，默克(Merck)股价处于三年来的高点。该公司超出了第三季度的预期，并提供了乐观的2021年前景，其中不包括抗病毒药物的潜在影响。该药丸刚刚在英国获得授权，将以Lagevrio的名称销售。</blockquote> Merck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.<blockquote>默克公司已经与美国政府达成了170万个疗程的莫努匹拉韦的协议。此外，它还同意向英国供应48万个疗程的该药物。它计划在2021年制作1000万门课程，在2022年至少制作2000万门课程。</blockquote> So, all in all, is Merck stock a buy or a sell right now?<blockquote>那么，总而言之，默克股票现在是买入还是卖出？</blockquote> Merck Stock Fundamentals: Sales Top<blockquote>默克股票基本面：销售额最高</blockquote> During the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.<blockquote>第三季度，调整后收益增长28%至每股1.75美元，销售额飙升20%至131.5亿美元。这两项指标都超出了预期。</blockquote> Merck also provided guidance following its&nbsp;Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.<blockquote>默克公司还提供了指导欧加农（OGN）分拆。该制药公司将全年调整后利润预期上调至每股5.65美元至5.70美元，销售额为474亿美元至479亿美元。两项指标均超出预期。而且它们不包括莫努匹拉韦在美国或欧洲获得授权的潜力。</blockquote> The company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.<blockquote>该公司最大的单一药物仍然是癌症治疗药物Keytruda。Keytruda占第三季度总销售额的三分之一以上。Keytruda销售额增长22%，达到45.3亿美元。其人乳头瘤病毒疫苗Gardasil的销售额飙升68%，达到19.9亿美元。</blockquote> But revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.<blockquote>但糖尿病药物Januvia的收入下降了1%，至13.4亿美元。默克公司报告称，由于新冠疫苗在美国占据优先地位，其肺炎疫苗Pneumovax 23的销量下降了26%。</blockquote> Overall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.<blockquote>总体而言，第三季度的指标符合CAN SLIM投资规则，该规则建议投资者寻找近期季度增长率为20%-25%或更高的公司。</blockquote> In the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.<blockquote>FactSet调查的分析师预计默克本季度每股收益为1.54美元，销售额为132亿美元。与去年同期相比，盈利将飙升近22%，销售额将增长5%以上。</blockquote> What Do Annual Metrics Say About Merck?<blockquote>年度指标对默克有何影响？</blockquote> As of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.<blockquote>截至11月30日收盘，默克股价年内下跌超过4%。股价最近创下至少三年来的新高，但此后一直在下跌。</blockquote> Last year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.<blockquote>去年，默克的销售额增长了2.5%，达到479.9亿美元。这一增长率较2019年11%的增长率有所放缓。</blockquote> For 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.<blockquote>分析师预计2021年销售额将小幅增长至484.9亿美元。收入预计将增长2.7%，达到每股5.81美元。此前，2020年将增长14%。</blockquote> The stock ranks fifth by&nbsp;Composite Rating&nbsp;in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.<blockquote>该股在制药公司行业中的综合评级排名第五。在《投资者商业日报》追踪的197家集团中，这家拥有33家公司的医疗道德药品集团排名中等，第95位。</blockquote> Merck Stock News: Merck Grabs Covid Deal<blockquote>默克股票新闻：默克获得新冠协议</blockquote> Merck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.<blockquote>默克公司的molnupiravir现已在英国获得授权。默克公司将向英国供应48万个疗程的该药物，目前以Lagevrio品牌销售。既然FDA的顾问已经推荐了molnupiravir，整个机构将考虑该药物。</blockquote> The U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.<blockquote>默克公司在美国购买170万门课程的交易价值12亿美元。如果成功，molnupiravir可能会在今年年底前进入美国市场。</blockquote> In addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and&nbsp;Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.<blockquote>除了默沙东和辉瑞，Atea制药公司（AVIR）和Enanta制药(ENTA)正在研究口服新冠药物。罗氏(RHHBY)最近退出了与Atea的Covid抗病毒药物交易。</blockquote> Analysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from&nbsp;Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and&nbsp;Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.<blockquote>分析师表示，与抗体药物相比，这些药物可能为新冠病毒的非住院治疗提供更容易的途径再生元制药（REGN），礼来公司（LLY）及维尔生物技术（来）。抗体药物必须由卫生保健专业人员给予。</blockquote> But there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.<blockquote>但有人担心莫努匹拉韦的作用方式可能会给未出生婴儿的DNA带来突变。因此，FDA顾问对是否推荐孕妇使用它犹豫不决。</blockquote> Further, Merck and&nbsp;Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.<blockquote>此外，默克和吉利德科学（GILD）开始了一项2期研究，测试他们口服HIV治疗的组合。这些药物被称为islatravir和lenacapavir，可以在体内停留很长时间。这意味着患者可以减少服药的频率。在这种情况下，这些公司正在测试每周给药方案。</blockquote> Merck also recently finished acquiring Acceleron.<blockquote>默克最近也完成了对Acceleron的收购。</blockquote> In early March, President Joe Biden announced Merck would help&nbsp;Johnson &amp; Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.<blockquote>三月初，乔·拜登总统宣布默克公司将提供帮助强生公司(JNJ)生产其新冠疫苗。默克公司将从生物医学高级研究与发展局获得2.688亿美元，以帮助扩大设施空间。</blockquote> Is Merck Stock A Buy Now?<blockquote>默克股票现在值得买入吗？</blockquote> Based on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.<blockquote>根据CAN SLIM投资规则，不，默克股票目前不值得买入。股价已经反复突破了之前的突破，并引发了多个卖出信号。</blockquote> There are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.<blockquote>还有进一步的警告。默克公司第三季度的销售额和盈利都可能低于预期。预计本季度的销售额不会达到这一目标。</blockquote> Still, big stocks like Merck can add gains without hitting massive growth streaks.<blockquote>尽管如此，像默克这样的大型股票可以在不实现大幅增长的情况下增加涨幅。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://www.investors.com/news/technology/merck-stock-buy-now/\">Investors</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRK":"默沙东"},"source_url":"https://www.investors.com/news/technology/merck-stock-buy-now/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1170675098","content_text":"Food and Drug Administration advisors recommended Merck's (MRK) Covid pill for some patients in late November, but Merck stock remains under pressure.\nThe FDA's Antimicrobial Drugs Advisory Committee voted 13-10 on Nov. 30, saying the benefits of the Ridgeback Biotherapeutics-partnered pill outweigh its risks. The pill, dubbed molnupiravir, reduced the risk of hospitalization or death in mild-to-moderate Covid patients with risk factors for severe disease.\nNext, the full FDA will mull the drug. The agency isn't bound by the committee's guidance. It could also authorize the pill for a broad group, though Merck only has test results so far in unvaccinated patients. Panelists noted there are concerns about molnupiravir in pregnant women.\nMerck is going up against Pfizer(PFE). The companies tested a similar patient group. But Merck's pill reduced the risk of severe outcomes by 30% when patients began treatment within five days of symptoms appearing. Pfizer's two-pill regimen cut the risk by 89% when treating within three days.\nPrior to its Pfizer-tied dive, Merck stock was trading at a three-decade high. The company beat third-quarter expectations and offered a bullish 2021 outlook that didn't include the potential impact of the antiviral pill. The pill just gained authorization in the U.K. where it will sell under the name Lagevrio.\nMerck already has a deal with the U.S. government for 1.7 million courses of molnupiravir. Further, it has agreed to supply the U.K. with 480,000 courses of the drug. It plans to make 10 million courses in 2021 and at least 20 million in 2022.\nSo, all in all, is Merck stock a buy or a sell right now?\nMerck Stock Fundamentals: Sales Top\nDuring the third quarter, adjusted earnings climbed 28% to $1.75 per share and sales soared 20% to $13.15 billion. Both metrics beat forecasts.\nMerck also provided guidance following its Organon(OGN) spinoff. The pharma company boosted its full-year outlook to adjusted profit of $5.65-$5.70 per share on $47.4 billion to $47.9 billion in sales. Both measures topped expectations. And they don't include the potential for molnupiravir to gain authorizations in the U.S. or Europe.\nThe company's biggest single drug remains cancer treatment Keytruda. Keytruda accounted for more than a third of total third-quarter sales. Keytruda sales increased 22% to $4.53 billion. Sales of its human papillomavirus vaccine, Gardasil, soared 68% to $1.99 billion.\nBut revenue from diabetes med Januvia fell 1% to $1.34 billion. And Merck reported a 26% decline for its pneumonia vaccine, Pneumovax 23, as Covid vaccines took priority in the U.S.\nOverall, third-quarter metrics were in line withCAN SLIM rules for investing,which advise investors to look for companies with recent quarterly growth of 20%-25%, or better.\nIn the current quarter, analysts polled by FactSet expect Merck to earn $1.54 per share on $13.2 billion in sales. On a year-over-year basis, earnings would surge almost 22% and sales would rise north of 5%.\nWhat Do Annual Metrics Say About Merck?\nAs of the close on Nov. 30, Merck stock was down more than 4% for the year. Shares recently hit at least a three-decade high, but have since tumbled.\nLast year, Merck's sales grew 2.5% to $47.99 billion. That decelerated from 11% growth in 2019.\nFor 2021, analysts expect sales to rise a fraction to $48.49 billion. Income is projected to inch 2.7% higher to $5.81 a share. That follows 14% growth in 2020.\nThe stock ranks fifth by Composite Rating in the industry group of pharma companies. The 33-company Medical-Ethical Drugs group ranks a middling No. 95 out of 197 groups tracked by Investor's Business Daily.\nMerck Stock News: Merck Grabs Covid Deal\nMerck's molnupiravir is now authorized in the U.K. Merck will supply the U.K. with 480,000 courses of the drug, now selling under the brand name Lagevrio. Now that the FDA's advisors have recommended molnupiravir, the full agency will consider the drug.\nThe U.S. deal for 1.7 million courses is worth $1.2 billion to Merck. If successful, molnupiravir could hit the U.S. market before the end of the year.\nIn addition to Merck and Pfizer,Atea Pharmaceuticals(AVIR) and Enanta Pharmaceuticals(ENTA) working on oral Covid drugs.Roche(RHHBY) recently pulled out of its deal with Atea for the Covid antiviral.\nAnalysts say the pills could offer an easier route for non-hospitalized treatment of Covid than antibody drugs from Regeneron Pharmaceuticals(REGN),Eli Lilly(LLY) and Vir Biotechnology(VIR). Antibody drugs must be given by health care professionals.\nBut there is some concern that the way molnupiravir works could introduce mutations into the DNA of an unborn baby. So, FDA advisors waffled on whether to recommend its use for pregnant women.\nFurther, Merck and Gilead Sciences(GILD) began a Phase 2 study testing a combination of their oral HIV treatments. The drugs, known as islatravir and lenacapavir can stay in the body for a long time. This means patients can take medicine less frequently. In this case, the companies are testing a weekly dosing regimen.\nMerck also recently finished acquiring Acceleron.\nIn early March, President Joe Biden announced Merck would help Johnson & Johnson(JNJ) produce its Covid vaccine. Merck will receive $268.8 million from the Biomedical Advanced Research and Development Authority to help expand facility space to do so.\nIs Merck Stock A Buy Now?\nBased on CAN SLIM rules for investing, no, Merck stock is not a buy right now. Shares have round-tripped their earlier breakout and have triggered several sell signals.\nThere are further caveats. Both Merck's sales and earnings met CAN SLIM guidelines in the third quarter. Sales aren't expected to meet that mark in the current quarter.\nStill, big stocks like Merck can add gains without hitting massive growth streaks.","news_type":1,"symbols_score_info":{"MRK":0.9}},"isVote":1,"tweetType":1,"viewCount":895,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":7,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/603062571"}